Immunoharmacology of hypersensitivity reactions to drugs

Current Allergy and Asthma Reports

Volumn 3, Issue 1, 2003, Pages 22-29

  Naisbitt, Dean J ^a   Pirmohamed, Munir ^a   Park, B Kevin ^a  

^a UNIVERSITY OF LIVERPOOL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

1 FLUORO 2,4 DINITROBENZENE; ABACAVIR; AMOXICILLIN; ANTINEOPLASTIC AGENT; CARBAMAZEPINE; CEPHALOSPORIN; CYTOCHROME P450; CYTOKINE; ENFLURANE; GAMMA INTERFERON; GLUTATHIONE; HALOTHANE; HAPTEN; HLA DR ANTIGEN; IMMUNOGLOBULIN E; IMMUNOGLOBULIN G; INTERLEUKIN 12; INTERLEUKIN 13; INTERLEUKIN 2; ISOFLURANE; ISONIAZID; LAMOTRIGINE; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; PARACETAMOL; PENICILLIN G; PHENINDIONE; PHENOBARBITAL; SULFAMETHOXAZOLE; TUMOR NECROSIS FACTOR ALPHA; UNINDEXED DRUG; DRUG;

ANTIGEN PRESENTATION; ANTIGEN PRESENTING CELL; ARTHRALGIA; CLINICAL FEATURE; COVALENT BOND; CYTOKINE RELEASE; DISEASE PREDISPOSITION; DOSE RESPONSE; DRUG ACTIVATION; DRUG DETOXIFICATION; DRUG ERUPTION; DRUG HYPERSENSITIVITY; DRUG INACTIVATION; DRUG METABOLISM; DRUG PROTEIN BINDING; DRUG UPTAKE; EOSINOPHILIA; EPSTEIN BARR VIRUS; FEVER; GENETIC PREDISPOSITION; HEPATITIS; HUMAN; HUMAN HERPESVIRUS 6; HUMAN IMMUNODEFICIENCY VIRUS; HYPOTHESIS; IMMUNE RESPONSE; IMMUNOLOGICAL TOLERANCE; IMMUNOPHARMACOLOGY; LIVER METABOLISM; LYMPHADENOPATHY; NONHUMAN; OUTCOMES RESEARCH; OXIDATIVE STRESS; PHARMACOGENETICS; PHYSICAL STRESS; PREDICTION; REVIEW; RISK FACTOR; SIGNAL TRANSDUCTION; TH1 CELL; TH2 CELL; VIRUS INFECTION; IMMUNE SYSTEM; IMMUNOLOGY; METABOLISM; PATHOPHYSIOLOGY;

DRUG HYPERSENSITIVITY; HUMANS; IMMUNE SYSTEM; PHARMACEUTICAL PREPARATIONS;

EID: 0038687268     PISSN: 15297322     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11882-003-0006-9     Document Type: Review

References (50)

1. Pirmohamed M, Breckenridge AM, Kitteringham NR, Park BK: Adverse drug reactions. BMJ 1998, 316:1295-1298.
2. Park BK, Pirmohamed M, Kitteringham NR: Idiosyncratic drug reactions: a mechanistic evaluation of risk factors. Br J Clin Pharmacol 1992, 34:377-395.
3. Sullivan JR, Shear NH: The drug hypersensitivity syndrome: What is the pathogenesis? Arch Dermatol 2001, 137:357-364.
4. Wong IC, Mawer GE, Sander JW: Factors influencing the incidence of lamotrigine-related skin rash. Ann Pharmacother 1999, 33:1037-1042.
5. Knowles SR, Uetrecht J, Shear NH: Idiosyncratic drug reactions: the reactive metabolite syndromes. Lancet 2000, 356:1587-1591.
6. Neuberger J, Kenna JG: Halothane hepatitis: a model of immunoallergic disease. In Liver Cells and Drugs. Edited by John Libbey. Montrouge, rance: Eurotext; 1988:161-173.
7. Pohl LR, Kenna JG, Satoh H, Christ D: Neoantigens associated with halothane hepatitis. Drug Metab Rev 1989, 20:203-217.
8. Kenna JG, Knight TL, van Pelt FNAM: Immunity to halothane metabolite-modified proteins in halothane hepatitis. Ann NY Acad Sci 1993, 685:646-661.
9. Park BK, Pirmohamed M, Kitteringham NR: The role of drug disposition in drug hypersensitivity: a chemical, molecular and clinical perspective. Chem Res Toxicol 1998, 11:969-988.
10. Naisbitt DJ, Williams DP, Pirmohamed M, et al.: Reactive metabolites and their role in adverse drug reactions. Curr Opin Allergy Clin Immunol 2001, 1:317-325.
11. Uetrecht JP: New concepts in immunology relevant to idiosyncratic drug reactions: the "danger hypothesis" and innate immune system. Chem Res Toxico. 1999, 12:387-395.
12. Landsteiner K, Jacobs J: Studies on the sensitisation of animals with simple chemical compounds. J Exp Med 1935, 61:643-656.
13. Park BK, Coleman JW, Kitteringham NR: Drug disposition and drug hypersensitivity. Biochem Pharmacol 1987, 36:581-590.
14. Naisbitt DJ, Gordon SF, Pirmohamed M, et al.: Antigenicity and immunogenicity of sulphamethoxazole: demonstration of metabolism-dependent haptenation and T-cell proliferation in vivo. Br J Pharmacol 2001, 133:295-305.
15. Naisbitt DJ, Farrell J, Gordon SF, et al.: Covalent binding of the nitroso metabolite of sulfamethoxazole leads to toxicity and major histocompatibility complex-restricted antigen presentation. Mol Pharmacol 2002, 62:628-637.
16. Kalish RS, Askenase PW: Molecular mechanisms of CD8+ T cell-mediated delayed hypersensitivity: implications for allergies, asthma and autoimmunity. J Allergy Clin Immunol 1999, 103:192-199.
17. Naisbitt DJ, Gordon SF, Pirmohamed M, Park BK: Immunological principles of adverse drug reactions: the initiation and propagation of immune responses elicited by drug treatment. Drug Saf 2000, 23:483-507.
18. Gut J, Christen U, Huwyler J: Mechanisms of halothane toxicity: novel insights. Pharmacol Ther 1993, 58:133-155.
19. Njoku D, Laster MJ, Gong DH, et al.: Biotransformation of halothane, enflurane, isoflurane, and desflurane to trifluoroacetylated liver proteins: association between protein acylation and hepatic injury. Anesth Analg 1997, 84:173-178.
20. Baron JM, Holler D, Schiffer R, et al.: Expression of multiple cytochrome P450 enzymes and multidrug resistance-associated transport proteins in human skin keratinocytes. J Invest Dermatol 2001, 116:541-548.
21. Reilly TP, Lash LH, Doll MA, et al.: A role for bioactivation and covalent binding within epidermal keratinocytes in sulfonamide-induced cutaneous drug reactions. J Invest Dermatol 2000, 114:1164-1173.
22. Uetrecht J: Generation by phagocytes of reactive drug metabolites. Exp Hematol 1995, 23:778-814.
23. Williams DP, Pirmohamed M, Naisbitt DJ, et al.: Induction of metabolism-dependent and -independent neutrophil apoptosis by clozapine. Mol Pharmacol 2000, 58:207-216.
24. Zanni MP, von Greyerz S, Schnyder B, et al.: HLA-restricted, processing- and metabolism-independent pathway of drug recognition by human alpha beta T lymphocytes. J Clin Invest 1998, 102:1591-1598.
25. Schnyder B, Burkhart C, Schnyder-Frutig K, et al.: Recognition of sulfamethoxazole and its reactive metabolites by drug-specific CD4+ T cells from allergic individuals. J Immunol 2000, 164:6647-6654.
26. Hertl M, Jugert F, Merk HF: CD8(+) dermal T-cells from a sulfamethoxazole-induced bullous exanthem proliferate in response to drug-modified liver-microsomes. Br J Dermatol 1995, 132:215-220.
27. Matzinger P: Tolerance, danger, and the extended family. Annu Rev Immunol 1994, 12:991-1045.
28. Gallucci S, Lolkema M, Matzinger P: Natural adjuvants: endogenous activators of dendritic cells. Nat Med 1999, 5:1249-1255.
29. Curtsinger JM, Schmidt CS, Mondino A, et al.: Inflammatory cytokines provide a third signal for activation of naive CD4+ and CD8+ T cells. J Immunol 1999, 162:3256-3262.
30. Descamps V, Valance A, Edlinger C, et al.: Association of human herpesvirus 6 infection with drug reaction with eosinophilia and systemic symptoms. Arch Dermatol 2001, 137:301-304.
31. Pirmohamed M, Park BK: HIV and drug allergy. Curr Opin Allergy Clin Immunol 2001, 1:311-316.
32. Baier-Bitterlich G, Fuchs D, Wachter H: Chronic immune stimulation, oxidative stress, and apoptosis in HIV infection. Biochem Pharmacol 1997, 53:755-763.
33. Schnyder B, Frutig K, Mauri-Hellweg D, et al.: T-cell-mediated cytotoxicity against keratinocytes in sulfamethoxazole-induced skin reaction. Clin Exp Allergy 1998, 28:1412-1417.
34. Naldi L, Conforti A, Venegoni M, et al.: Cutaneous reactions to drugs. An analysis of spontaneous reports in four Italian regions. Br J Clin Pharmacol 1999, 48:839-846.
35. Lepoittevin JP, Leblond I: Hapten peptide T-cell receptor interactions: molecular basis for the recognition of haptens by T-lymphocytes. Eur J Dermatol 1997, 7:151-154.
36. Kimber I, Dearman RJ: Allergic contact dermatitis: the cellular effectors. Contact Dermatitis 2002, 46:1-5.
37. Kehren J, Desvignes C, Krasteva M, et al.: Cytotoxicity is mandatory for CD8+ T cell-mediated contact hypersensitivity. J Exp Med 1999, 189:779-786.
38. Akiba H, Kehren J, Ducluzeau MT, et al.: Skin inflammation during contact hypersensitivity is mediated by early recruitment of CD8+ T cytotoxic 1 cells inducing keratinocyte apoptosis. J Immunol 2002, 168:3079-3087.
39. Friedmann PS, Strickland I, Pirmohamed M, Park BK: Investigation of mechanisms in toxic epidermal necrolysis induced by carbamazepine. Arch Dermatol 1994, 130:598-604.
40. Madden S, Maggs JL, Park BK: Bioactivation of carbamazepine in the rat in vivo: evidence for the formation of reactive arene oxide(s). Drug Metab Dispos 1996, 24:469-479.
41. Maggs JL, Naisbitt DJ, Tettey JN, et al.: Metabolism of lamotrigine to a reactive arene oxide intermediate. Chem Res Toxicol 2000, 13:1075-1081.
42. Dorner BG, Scheffold A, Rolph MS, et al.: MIP-1alpha, MIP-1beta, RANTES, and ATAC/lymphotactin function together with IFN-gamma as type 1 cytokines. Proc Natl Acad Sci U S A 2002, 99:6181-6186.
43. Yawalkar N, Hari Y, Frutig K, et al.: T cells isolated from positive epicutaneous test reactions to amoxicillin and ceftriaxone are drug specific and cytotoxic. J Invest Dermatol 2000, 115:647-652.
44. Hashizume H, Takigawa M, Tokura Y: Characterization of drug-specific T cells in phenobarbital-induced eruption. J Immunol 2002, 168:5359-5368.
45. Batchelor JR, Welsh KI, Tinoco RM, et al.: Hydralazine-induced systemic lupus erythematosus: influence of HLA-DR and sex on susceptibility. Lancet 1980, 1:1107-1109.
46. Pirmohamed M, Park BK: Genetic susceptibility to adverse drug reactions. Trends Pharmacol Sci 2001, 22:298-305.
47. Green VJ, Pirmohamed M, Kitteringham NR, et al.: Genetic analysis of microsomal epoxide hydrolase in patients with carbamazepine hypersensitivity. Biochem Pharmacol 1995, 50:1353-1359.
48. Pirmohamed M, Lin K, Chadwick D, Park BK: TNF-alpha promoter region gene polymorphisms in carbamazepine-hypersensitive patients. Neurology 2001, 56:890-896.
49. Mallal S, Nolan D, Witt C, et al.: Association between presence of HLA-B*5701, HLA-DR7, and HLA-DQ3 and hypersensitivity to HIV-1 reverse transcriptase inhibitor abacavir. Lancet 2002, 359:727-732.
50. Hetherington S, Hughes AR, Mosteller M, et al.: Genetic variations in HLA-B region and hypersensitivity reactions to abacavir. Lancet 2002, 359:1121-1122.